---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-141488"
form_type: "8-K"
ticker: "DBVT"
cik: "0001613780"
company_name: "DBV Technologies S.A."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:12:02.098635+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# DBV Technologies announces NEJM publication of Phase 3 EPITOPE trial for Viaskin Peanut in toddlers

## Summary
- NEJM published Phase 3 EPITOPE data showing Viaskin Peanut statistically superior to placebo in desensitizing toddlers (1-3 years) to peanut.
- Treatment responder rates: 67.0% for Viaskin Peanut vs 33.5% for placebo after 12 months.
- No FDA-approved treatment options exist for peanut-allergic children under 4 years; DBV is advancing regulatory efforts for this age group.
- Viaskin Peanut was well-tolerated with low rates of treatment-related anaphylaxis and epinephrine use; local application site reactions decreased over time.
- Editorial in NEJM called the data 'very good news' for toddlers with peanut allergy.

## SEC filing metadata
- accession: 0001193125-23-141488
- form_type: 8-K
- ticker: DBVT
- cik: 0001613780
- company_name: DBV Technologies S.A.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1613780/000119312523141488/0001193125-23-141488-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1613780/000119312523141488/d237467d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-141488
- JSON: https://secwatch.observer/filing/0001193125-23-141488.json
- Plain text: https://secwatch.observer/filing/0001193125-23-141488.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.